Drug policy fellow Katharine A. Neill explains why establishing heroin-assisted treatment programs, which provide severely addicted individuals with controlled access to pharmaceutical-grade heroin, could make a significant dent in the number of U.S. deaths from opioid use in this post for the Baker Institute Blog.
James A. Baker, III, and George P. Shultz — both former secretaries of state and Treasury secretaries — offer "A Conservative Answer to Climate Change" in a commentary for The Wall Street Journal.
James A. Baker, III, George P. ShulzFebruary 15, 2017
Understood in its regional context, Philippines President Rodrigo Duterte’s war on drugs appears to be a continuation rather than a departure from Southeast Asian drug policy.
In this blog post, Mexico Center director Tony Payan discusses the results of Mexico's June 5 election and what they mean for the country's 2018 presidential election.
While Mexico may indeed emerge from the recent oil price slump in better shape than most, tinkering with the solid macroeconomic foundations established by the country’s last three administrations could lead to trouble.
Baker Institute experts explain how Friday's arrest of Mexican drug lord Joaquin "El Chapo" Guzman will affect the Peña Nieto administration, the Sinaloa Cartel and the Mexican government's "kingpin strategy" to destroy the cartels.
Tony Payan, Gary J. Hale, Nathan P. JonesJanuary 9, 2016
Katharine Neill, the Alfred C. Glassell, III Postdoctoral Fellow in Drug Policy, explains what you should know about the Justice Department's plan to release 6,000 nonviolent drug offenders from federal prison during four days in October and November.
A new White House initiative to address rising U.S. heroin use will increase funds to pinpoint the sources of heroin as well as hot spots for drug overdoses. Baker Institute Blog: http://bit.ly/1h0W7r2
In physics, extensive collaborations, access to colleagues’ data and rigorous peer review make it extremely difficult for individual researchers to bend the rules. Furthermore, physics does not harbor the types of ethical minefields characteristic of the biosciences. No thorny questions arise pertaining to human or animal life, nor do physicists commonly grapple with the ethical haze of intellectual property when patents and money are at stake. Things seem to be black and white in physics. But are they?
Elaine Howard Ecklund, Kirstin R.W. MatthewsJune 1, 2015